| セッション情報 |
International Session2(肝臓学会・消化器病学会合同)
Gene therapy and cell therapy through the liver; current aspects and future prospects
|
| タイトル |
肝IS2-3：Novel immunotherapy using liver natural killer cells for preventing recurrence of hepatocellular carcinoma in liver transplantation.
|
| 演者 |
M. Ohira（The Second Department of Surgery, Hiroshima University） |
| 共同演者 |
S. Nishida（Department of Surgery, University of Miami）, H. Ohdan（The Second Department of Surgery, Hiroshima University） |
| 抄録 |
Tumor recurrence is the main limitation of liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) and can be promoted by immunosuppressants. However, there is no prevention or treatment for HCC recurrence after LT. Here, we describe an adoptive immunotherapy approach that uses natural killer (NK) cells derived from both living and cadaveric donor liver graft perfusate. In Japan, we successfully applied this approach to 27 liver cirrhotic patients with HCC. The median follow up time is 49.4 (9-84) months. Focusing on the recipients exceeding the Milan criteria (n=13), the recurrent free survival (RFS) rates were significantly improved in the NK therapy group compared to that in the control group (n=8); 3 year-RFS 79% and 25%, respectively (Log rank test p=0.002).We applied this immunotherapy to the cadaveric donor liver transplantation in US. After obtaining approval from the FDA and IRB of our institute, we successfully applied this approach to 17 liver cirrhotic patients with HCC (Clinicaltrial.gov #NCT01147380). The median follow up time is 16 (3-29) months. Only one patient with sarcoma and lymph node metastasis had recurrence. There are no study related adverse events. In conclusion, the administration of IL-2-stimulated NK cells derived from both living and cadaveric donor is well tolerated and could be a novel treatment after LT with HCC. |
| 索引用語 |
HCC, NK cell |
